ArticleInvestigational new drugs2014

Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.

Nicole Grabinski et al.PubMed ↗Publisher ↗

No numbers read from the abstract.